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Abstract
Background: KAI1 was initially identified as a metastasis-suppressor gene in prostate cancer. It is a member of the
tetraspan transmembrane superfamily (TM4SF) of membrane glycoproteins. As part of a tetraspanin-enriched
microdomain (TEM), KAI1 inhibits tumor metastasis by negative regulation of Src. However, the underlying
regulatory mechanism has not yet been fully elucidated. CUB-domain-containing protein 1 (CDCP1), which was
previously known as tetraspanin-interacting protein in TEM, promoted metastasis via enhancement of Src activity.
To better understand how KAI1 is involved in the negative regulation of Src, we here examined the function of
KAI1 in CDCP1-mediated Src kinase activation and the consequences of this process, focusing on HIF-1 a and VEGF
expression.
Methods: We used the human prostate cancer cell line PC3 which was devoid of KAI1 expression. Vector-
transfected cells (PC3-GFP clone #8) and KAI1-expressing PC3 clones (PC3-KAI1 clone #5 and #6) were picked after
stable transfection with KAI1 cDNA and selection in 800 μg/ml G418. Protein levels were assessed by
immunoblotting and VEGF reporter gene activity was measured by assaying luciferase activitiy. We followed tumor
growth in vivo and immunohistochemistry was performed for detection of HIF-1, CDCP1, and VHL protein level.
Results: We demonstrated that Hypoxia-inducible factor 1a (HIF-1a) and VEGF expression were significantly
inhibited by restoration of KAI1 in PC3 cells. In response to KAI1 expression, CDCP1-enhanced Src activation was
down-regulated and the level of von Hippel-Lindau (VHL) protein was significantly increased. In an in vivo
xenograft model, KAI1 inhibited the expression of CDCP1 and HIF-1a.
Conclusions: These novel observations may indicate that KAI1 exerts profound metastasis-suppressor activity in the
tumor malignancy process via inhibition of CDCP1-mediated Src activation, followed by VHL-induced HIF-1a
degradation and, ultimately, decreased VEGF expression.
Background
More than 20 metastasis-suppressor genes encoding
products with specific metastasis-suppressing functions
have been discovered [1]. KAI1 (CD82) was first identi-
fied as a prostate cancer metastasis suppressor through
genetic screening [2]. Studies have shown that the
expression of KAI1 is actually down-regulated in most
metastatic cancers [3]. Consistent with this, reduced
KAI1 expression is associated with malignant progres-
sion of human prostate cancer [4]. KAI1 is a member of
the tetraspan transmembrane superfamily (TM4SF) of
type III membrane proteins, specifically of the tetraspa-
nin subgroup. It is ubiquitously expressed, especially in
spleen, thymus, prostate and colon, and interacts with a
large number of proteins, including integrins, epidermal
growth factor receptor (EGFR), and other tetraspanins.
KAI1 plays a role in organizing associated proteins into
functional signaling networks that influence the
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web [5].
Metastasis is the final step in the tumor progression
processes and involves increased invasiveness, extravasa-
tion into secondary organs, and angiogenesis [6].
Because cancer progression and metastasis involves mul-
tiple steps with a high degree of complexity, it requires
the contribution of a variety of molecules. Hypoxia,
which is the environmental factor best known to induce
cancer metastasis, up-regulates the expression of vascu-
lar endothelial growth factor (VEGF), which, in turn,
induces the formation of tumor-feeding vessels [7]. It
has been documented that the transcription factor,
hypoxia-inducible factor 1 a (HIF-1a), is stabilized in
the context of reduced oxygen availability and stimulates
the expression of VEGF [8]. An important step in HIF-
1a induction is closely related to the activity of the
tumor suppressor, von Hippel-Lindau (VHL) protein.
VHL is viewed primarily as an ubiquitin ligase for HIF-
1a that promotes the proteasome-dependent proteolytic
degradation of HIF-1a [9]. Generally, a loss of VHL
expression in cancer leads to up-regulation of HIF-1a
and increased VEGF expression [10].
A previous proteomic analysis of the tetraspanin com-
plex revealed CDCP1 as a new component of the tetra-
spanin web, showing that it was co-localized with
tetraspanin proteins, including KAI1(CD82), CD81, and
CD9 [11]. CDCP1 acts as metastasis enhancer through
tyrosine phosphorylation-dependent interactions with
Src and PKCδ [12,13]. It is a transmembrane protein
with three extracellular CUB domains, named for the
first three identified proteins (complement factor C1r/
C1s, embryonic sea urchin protein uEGF, and bone
morphogenic protein-1) containing such a domain.
Highest levels of CDCP1 expression are found in colon,
skin, small intestine, and prostate [14-16]. One tetraspa-
nin protein, CD9, has been shown to be a CDCP1-bind-
ing protein [12], but certain features of the interaction
of CDCP1 with tetraspanin proteins have not been fully
defined. Significantly, inhibiting CDCP1 with an anti-
CDCP1 antibody was shown to block tumor growth and
metastasis in prostate cancer [16].
Recent studies have revealed that KAI1 attenuates
EGFR, integrin, and c-Met signaling, confirming the
involvement of KAI1 in the intracellular signaling path-
ways associated with these molecules [3,5]. Moreover,
KAI1 expression is reported to inhibit activation of Src
kinase in prostate cancer cells [17-20]. The CDCP1-
interacting protein Src–the most extensively character-
ized number of the family of nonreceptor tyrosine
kinases–can dominantly contribute to cancer progres-
sion, angiogenesis, and metastasis [21]. In particular,
Elevation of Src is functionally linked to the develop-
ment of prostate cancer [22]. Thus, how KAI1 interrupts
Src kinase activation–a step required for suppression of
metastasis–becomes an essential question.
To better understand how KAI1 is involved in the
negative regulation of Src and inhibition of metastasis,
we postulated an interrelationship between KAI1 and
CDCP1 in regulation of Src activity in TEM. To test
this supposition, we here examined the function of
KAI1 in CDCP1-mediated Src kinase activation and the
consequences of this process, focusing on VEGF expres-
sion. Restoration of KAI1 expression in PC3 human
prostate carcinoma cells blocked Src activation through
negative regulation of CDCP1. Notably, HIF-1a and
VEGF expression were significantly inhibited by KAI1-
mediated Src inactivation and subsequent VHL up-regu-
lation. Importantly, KAI1 inhibited the expression of
CDCP1 and HIF-1a in an in vivo tumor xenograft
model. These novel findings may indicate that KAI1
functions as a profoundly effective metastasis suppressor
in the process of tumor malignancy and angiogenesis
through inhibition of CDCP1-mediated Src activation
and a subsequent dramatic reduction in HIF-1a and
VEGF expression via functional activation of VHL.
These studies may shed light on the mechanism by
which KAI1 suppresses prostate cancer metastasis.
Methods
Cell culture
PC3 cells (ATCC
® CRL-1435) were maintained in RPMI
medium 1640 supplemented with 10% heat-inactivated
fetal bovine serum and antibiotics. Before exposure to
hypoxia, culture medium was replaced by a thin layer of
fresh medium (0.15 ml/cm
2). Cells were transferred to a
Bactron Anaerobic/Environmental Chamber (Sheldon
Manufacturing, Inc.), which was flushed with 1% O2,5 %
CO2,a n d9 5 %N 2 at 37°C. In hypoxia-mimic experi-
ments, cells were incubated with 100 μMo fC o C l 2
under normoxic conditions.
Plasmids and transfection
Plasmid of GFP tagged KAI1 was gifted by Dr. Kyung
Keun Kim (Chonnam National University, Korea).
VEGF-luc promoter-reporter construct (2.2 kb) and HA
tagged VHL expresson vector were also gifted by Dr.
Joohun Ha (Kyunghee University, Korea) and Dr. Hong-
Duk Youn (Seoul National University, Korea) respec-
tively. HIF-1a expression plasmid was provided by
Addgene. Predesigned small interfering RNA (si-RNA)
for KAI1, VHL, and PKCδ were purchased from Santa
C r u zB i o t e c h n o l o g y ,I n c( S a n t aC r u z ,C A ,U S A ) .S i -
RNA for CDCP1 was purchased from Dharmacon
(Lafayette, CO). For transient transfection, PC3 cells
were plated on 6-well plate 1 day before transfection as
ad e n s i t yo f1 0
5/well. After 24 h, cells were transfected
with plasmids or siRNA using LipofectAMINE 2000
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of KAI1, PC3 (KAI1-/-) cells were transfected with GFP-
KAI1 expression plasmid. Vector-transfected cells (PC3-
GFP clone #8) and KAI1-expressing PC3 clones (PC3-
KAI1 clone #5 and #6) were picked after selection in
800 μg/ml G418.
Immunoblotting and imuoprecipitation
For polyacrylamide gel electrophoresis (PAGE), the cells
were washed with PBS twice and extracted in RIPA buf-
fer (150 mM NaCl, 50 mM Tris, pH 8.0, 1% NP-40,
0.25% sodium deoxycholate, 0.5% sodium lauryl sulfate,
1 mM EDTA). Cell lysates were centrifuged and super-
natants were collected. For immunoprecpiation, cell
extracts were incubated with antibody (1:1000 dilutions)
with constant agitation at 4°C overnight. After electro-
phoresis, proteins were transferred to nitrocellulose
membrane. Membranes were blocked with 1% bovine
serum albumin. Then, protein levels were detected using
the following commercial antibodies: anti-HIF-1 a, anti-
integrin b1, anti-E-cadherin, anti-N-cadherin, and anti-
FAK
397 (BD Biosciences, Franklin Lakes, NJ, USA); anti-
CDCP1, anti-phospho-p130CAS
Y410, anti-phospho-
Src
Y416, anti-Src, and anti-VHL (Cell Signaling Technol-
ogy, Danvers, MA, USA); anti-GFP, anti-PKC δ,a n t i -
KAI1, anti-HA, anti-FAK, anti-snail, anti-VHL, anti-pax-
illin, and anti-b actin (Santa Cruz Biotechnology, Santa
Cruz, CA, USA).
In vitro migration assay
Cell migration assays were performed using Boyden
chamber as previously described [18]. Cells were plated
on the upper side of a polycarbonate membrane separat-
ing two chambers of 6.5 mm Transwell culture plates
(Costar, Corning, NY, USA). After 24 hours, cells on the
upper face of the membrane were scraped using a cot-
ton swab and cells that had migrated to the lower face
of the membrane were stained with DiffQuick (Baxter
Scientific, Deerfield, IL USA) Wright-Giemsa Solution.
In vitro invasion assay
Cell invasion assay was performed on a matrigel inva-
sion chamber (BD Biocoat, BD biosciences, Bedford,
MA, USA). This experiment was set up identically to
the cell migration assay. After 72 hours, cells remaining
upper face of the membrane were scraped using a cot-
ton swab and cells that had invaded to the lower face of
t h em e m b r a n ew e r es t a i n e dw i t hD i f f Q u i c k( B a x t e r
Scientific, Deerfield, IL USA) Wright-Giemsa Solution.
Reverse Transcription-polymerase
Chain Reaction (RT-PCR)
Total RNA was extracted with Trizol reagent (Invitrogen,
Carlsbad, CA, USA). The cDNA fragment was amplified
by PCR using following specific primers: CDCP1, sense
5’-CTTCAACCTCTCCAACTGTG-3’ and antisense
5’-TGGTCTGTGCAGCTTATGGT-3’, HIF-1a,s e n s e5 ’-
CTTGCTCATCAGTTGCCACTT-3’,a n da n t i s e n s e
5’-GCCATTTCTGTGTGTAAGCAT-3’; VEGF, sense 5’-
CGAAGTGGTGAAGTTCATGGATG-3’, and antisense
5’- TTCTGTATCAGTCTTTCCTGGTGAG -3’; GLUT1,
sense 5’-CGGGCCAAGAGTGTGAA-3’, and antisense
5’- TGACGATACCGGAGCCAATG-3’,G A P D H ,s e n s e
5’-TGCTGAGTATGTCGTGGAGTCTA-3’,a n da n t i -
sense 5’-AGTGGGAGTTGCTGTTGAAGTCG-3’;
b-actin, sense 5’-GTGGGGGCGCCCAGGCACCA-3’,
and antisense 5’-CTCCTTAATGTCACGCACCATTTC-
3’. PCR was initiated in a thermal cycle programmed at
95°C for 5 min, 94°C for 45 s, 60°C for 2 min, and 72°C
for 2 min and amplified for 30 cycles. The amplified pro-
ducts were visualized on 1% agarose gels.
VEGF- promoter assay
PC3 cells were plated onto 6-well plates (5 × 10
5 cells/
well), and the following day cells were co-transfected
with a VEGF-luc promoter-reporter construct and KAI1
expression vector. Forty-eight hours after transfection,
reporter gene activity was measured by assaying lucifer-
ase activitiy (Promega, Madison, WI, USA), and normal-
ized to b-galactosidase activities (Promega, Madison,
WI, USA).
Tumor xenograft
Two million PC3 cells were resuspended in 100 μLP B S
and injected subcutaneously in the flanks of six-week-
old athymic nude mice (Balb/C, Charles River, Japan).
Tumor measurements were done with precision calipers
and animals were sacrificed after 35 days of injection.
Experiments were conducted according to the guidelines
for ethical use of animals of our Institution under an
approved protocol (approved number of this experiment
from ethical committee of animal experiment: KIRAMS
2011-5). Tumors were harvested and fixed overnight in
10% buffered formalin, embedded in paraffin, and sec-
tioned. Primary tumor volumes were calculated with the
formula: V = length × (width)
2/2.
Immunohistochemistry
Deparaffinized sections were rehydrated and antigen
retrieval was performed by 15 minutes incubation in
warm trypsin followed by microwave in 10 mM citrate
buffer for total of 10. Slides were then blocked with 3%
H2O2 followed by blocking in goat serum and primary
incubation at 4°C overnight. The slides were then
washed in Tris-NaCl buffer and incubated at room tem-
perature for 60 minutes with anti-CDCP1 antibody
(R&D systems, Minneapolis, MN, USA) at a 1:50 dilu-
tion, anti-HIF-1 antibody (Thermo Fisher Scientific,
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(Thermo Fisher Scientific, MA, USA) at a 1:50 dilution.
Slides were rinsed in Tris-NaCl buffer and incubated for
60 minutes with a biotinylated secondary antibody, bio-
tin polyclonal anti-rabbit immunoglobulin (for CDCP1
and VHL) (BD Transduction Laboratories, Lexington,
KY, USA) at a 1:200 dilution, or biotin polyclonal anti-
mouse immunoglobulin (for HIF-1) (BD Transduction
Laboratories, Lexington, KY, USA) (at a 1:100 dilution.
Secondary staining was performed and colorized using
Vectastain ABC Kit (Vector Laboratories, Burlingame,
CA, USA) and 3,3’-diaminobenzidine (DAB)-H2O2 sub-
strate (Sigma, St, Louis, MO). Slides were then counter-
stained with hematoxylin, dehydrated through graded
alcohols and xylene and mounted. Slides were studied
and imaged under brightfield microscopy.
Statistical analysis
Data are expressed as means ± standard deviations (SD)
of at least three experiments. Statistical significance was
determined using Student’s t-test for comparisons
between two means. The null hypothesis was rejected in
cases where p- values were < of 0.05. Densitometry of
immunoblots was performed by scanning of the exposed
film and using The Quantity one 1-D analysis software
(Bio-rad Laboratories, Inc, CA, USA)
Results
Restoration of KAI1 expression decreases phosphorylation
of Src kinase in PC3 prostate carcinoma cells
It has been proposed that KAI1 inhibits Src activation
[17-20]. Because KAI1 was initially identified as a metas-
tasis-suppressor gene in prostate cancer, we investigated
the metastasis-suppressor function of KAI1 in PC3
metastatic prostate cancer cells, focusing on Src inhibi-
tion. Src, a nonreceptor tyrosine kinase that transduces
signals that control metastasis, is autophosphorylated at
tyrosine residue 416 upon activation [23]. Thus, we
examined the tyrosine phosphorylation of Src. PC3 pros-
tate carcinoma cells, which were previously demon-
strated to have lost KAI1 expression, were transiently
transfected with a GFP-tagged KAI1 expression vector.
As shown in Figure 1A, the level of phosphorylated Src
(phospho-Src
416) was reduced by KAI1 expression. To
provide further support for this interpretation, we also
monitored the Src substrates, FAK and p130Cas. The
level of the tyrosine-phosphorylated, active forms of
FAK and p130Cas were decreased by KAI1 expression
(Figure 1A). Next, we stably transfected with a GFP-
tagged KAI1 expression vector. As PC3 prostate carci-
noma cells were devoid of KAI1 expression, Vector-
transfected cells (PC3-GFP clone number #8), and
KAI1- expressing PC3 clones (clone number #5 and #6)
were picked after stable transfection with KAI1 cDNA
and selection in 800 μg/ml G418. Cell surface expres-
sion of KAI1 was determined by FACS analysis (Figure
1B). Inhibition of migration and invasion in PC3-KAI1
stable transfectants were confirmed by transwell migra-
tion assays and invasion assay, respectively (Figure 1C).
Figure 1Dshows KAI1 expression in lysates from the
PC3-GFP vector clone (#8) and KAI1 stable transfec-
tants (#5 and #6) after immunoblotting with an anti-
GFP antibody. The cell motility-inhibitory function of
KAI1 was determined by examining the expression of E-
cadhesin, Snail, vimentin, paxilllin, and N-cadherin. As
shown in Figure 1A, D, KAI1 expression significantly
reduced the phosphorylation of Src at Tyr416, suggest-
ing that KAI1 inhibits Src activity. To confirm the effect
of KAI1 effect on Src activity, we transfected GFP vector
clones (PC3-GFP #8) and KAI1 stable transfectants
(PC3-KAI1 #6) with small interfering RNA (siRNA)
against KAI1 and analyzed Src phosphorylation. As
shown in Figure 1E, knockdown of KAI1 expression in
KAI1 stable transfectants (PC3-KAI1#6) reversed the
inhibition of Src kinase activity. Therefore, consistent
with previous reports, KAI1 expression contributes to
Src inhibition and suppression of cell migratory activity
in PC3 prostate cancer cells.
KAI1 acts through negative regulation of CDCP1 to
inhibit Src activity
Src kinase is a central element in multiple signaling
pathways that are important in tumor development,
functioning in oncogenesis through its interplay with
various upstream and downstream signaling molecules,
such as integrins, c-Met, and numerous growth factor
receptors [21]. Numerous studies have proposed that
KAI1 functions to limit integrin-mediated Src activation
[5,18-20]. However, we found that integrin b1 depletion
caused no specific changes in Src phosphorylation levels
(Figure 2A). Furthermore, altered band shift of integrin
beta 1 were observed by KAI1 expression (Figure 2C).
Therefore, we investigated another target of KAI1 pre-
sent in prostate cancer that interferes with Src signaling:
CDCP1. It has been noted that a high molecular weight
(HMW; 135-140 kDa) form of CDCP1 is processed
through interaction with a proteolytic enzyme to a
lower molecular weight form (LMW; ~80 kDa) [12,24].
Both HMW and LMW forms of CDCP1 can be tyro-
sine-phosphorylated by Src kinase. Expression of KAI 1
in PC3 cells significantly reduced the protein levels of
both HMW and LMW forms of CDCP1 and its inter-
acting protein, PKCδ ( F i g u r e2 B ,C ) .N o t a b l y ,R T - P C R
analyses showed no changes in CDCP1 mRNA levels
(Figure 2C). Next, the effect of KAI1 in CDCP1 levels
was examined by immunofluorescent microscopy.
CDCP1 was clearly stained in PC3 GFP vector clones.
By contrast, in the presence of KAI1, loss of CDCP1
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2D). To confirm KAI1-mediated negative regulation of
CDCP1, we treated siRNA of KAI1 in GFP vector clones
(#8) and KAI1 stable transfectants (#6). SiRNA-mediated
knockdown of KAI1 reversed the decrease in CDCP1
protein (Figure 2E). To clarify the effect of KAI1 on
CDCP1-mediated Src activation, we treated GFP vector
clones (#8) and KAI1 stable transfectants (#6) with
siRNA against CDCP1 and examined Src phosphoryla-
tion. As shown in Figure 2F, siRNA-mediated knock-
down of CDCP1 resulted in suppression of Src
phosphorylation, an effect that was also pronounced in
KAI1 stable transfectants (#6). Hence, KAI1 acts
through down-regulation of CDCP1 protein to inhibit
Src activation in PC3 prostate cancer cells.
KAI1 increases VHL protein levels
A recent report has linked loss of the VHL protein to
up-regulation of CDCP1 through HIF-1a-dependent
transcriptional activation [25]. The fact that KAI1
reduced CDCP1 protein levels in PC3 cells without sig-
nificant altering CDCP1 mRNA levels (see Figure 2C)
suggested that a posttranscriptional mechanism was
responsible for this action. To test this, we examined
the involvement of proteasome-dependent degradation
of CDCP1 in KAI1-expressing PC3 cells. As shown in
Figure 3A, treatment with the proteasome inhibitor
MG132 blocked the KAI1-induced reduction in CDCP1.
Earlier reports have proposed that the tumor-suppressor
function of the VHL protein reflects the role of VHL as
an ubiquitin ligase of the transcription factor HIF-1a,
Figure 1 Phosphorylation of Src at Tyr416 is inhibited by KAI1.( A) After transient transfection of KAI1 in PC3 prostate cancer cells,
phospho-Src
Y416, phospho-FAK
Y397, and phospho-p130Cas
Y410 protein levels were measured by immunoblotting. Densitometric analysis of
phospho-Src
Y416 was shown after normalization to beta-actin. (B) Vector-transfected cells (PC3-GFP clone #8) and KAI1-expressing PC3 clones
(PC3-KAI1 clone #5 and #6) were picked after stable transfection with KAI1 cDNA and selection in 800 μg/ml G418. Cell surface expression of
KAI1 was analyzed by flow cytometry. (C) The inhibitory effect of KAI1 on migration and invasion was confirmed in KAI1-expressing clones by
transwell migration assay and invasion assay, respectively. (D) Cell lysates were harvested and immunoblotted for GFP-KAI1, phospho-Src
Y416,
E-cadherin, Snail, vimentin, paxillin, and N-cadherin. Densitometric analysis of phospho-Src
Y416 was shown after normalization to beta-actin.
(E) Vector-transfected cells (PC3-GFP #8), and KAI1-expressing PC3 clones (PC3-KAI1 #6) were transiently transfected with siRNA against KAI1,
and then Src phosphorylation was monitored by immunoblotting. Densitometric analysis of phospho-Src
Y416 was shown after normalization
to beta-actin.
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Figure 2 KAI1-mediated negative regulation of CDCP1 inhibits Src.( A) Vector-transfected cells (PC3-GFP #8) and KAI1-expressing PC3 clones
(PC3-KAI1 #6) were transiently transfected with siRNA against integrin b1. Forty-eight hours after transfection, the levels of phospho-Src
Y416,
phospho-FAK
Y397, phospho-p130Cas
Y410, and integrin b1 were measured by immunoblotting. Densitometric analysis of phospho-Src
Y416 was
shown after normalization to beta-actin. (B) PC3 cells were transfected with KAI1. Twenty-four hours after transfection, phospho-Src
Y416 and
CDCP1 were detected by immunoblotting. Densitometric analysis of CDCP1 was shown after normalization to beta-actin. (C) Cell lysates from
PC3 vector control (PC3-GFP #8) and KAI1 transfectants (PC3-KAI1 #5 and PC3-KAI1 #6) were analyzed for CDCP1, phospho-Src
Y416, PKCδ, integrin
b1, and GFP-KAI1 protein levels. Densitometric analysis of CDCP1 was shown after normalization to beta-actin. (D) CDCP1 proteins were detected
by immunofluorescence using anti-CDCP1 antibody and visualized using rhodamine-labeled secondary antibody. (E) PC3 cells stably transfected
with KAI1 (PC3-KAI1 #6) and vector control (PC3-GFP #8) cells were treated with siRNA against KAI1. After 48 hours, cell lysates were analyzed by
immunoblotting to detect CDCP1 and GFP-KAI1. (F) After siRNA-mediated knockdown of CDCP1, phospho-Src
Y416 levels were monitored by
immunoblotting.
Park et al. BMC Cancer 2012, 12:81
http://www.biomedcentral.com/1471-2407/12/81
Page 6 of 14which is known as a master regulator of hypoxic
response. Moreover, it has been shown that Src destabi-
lizes the VHL protein [26]. Collectively, these observa-
tions suggest the possibility that KAI1, acting through
inhibition of Src, stabilizes VHL, resulting in the ubiqui-
tin/proteasome-dependent degradation of various pro-
teins. Thus, we hypothesized that KAI1 could inhibits
CDCP1-mediated enhancement of Src activation, result-
ing in subsequent stabilization of VHL. Although the
basal level of VHL could not be clearly detected, VHL
protein was readily observed in KAI1-expressing PC3
cells, indicating that the res t o r a t i o no fK A I 1i n c r e a s e d
VHL protein levels (Figure 3B). In order to confirm the
increase in VHL protein, we transfected GFP vector
clones (PC3-GFP#8) and KAI1 stable transfectants
( P C 3 - K A I 1# 5a n dP C 3 - K A I 1# 6 )w i t ha nH A - t a g g e d
VHL expression vector and then analyzed the amount
of VHL protein. As shown in Figure 3C, there was a
dramatic increase in VHL protein levels in KAI1 stable
transfectants (PC3-KAI1#5 and PC3-KAI1 #6) transi-
ently overexpressing VHL, confirming that KAI1
increased VHL protein level. Notably, overexpression of
VHL in PC3 cells was associated with a decrease in
CDCP1 protein levels (Figure 3D). The VHL-induced
decrease of CDCP1 is consistent with the recovery of
CDCP1 levels by treatment of KAI1 stable transfectants
(PC3-KAI1 #6) with MG132 (Figure 3A). Taken
together, these results suggest that increased VHL activ-
ity in the context of KAI1 protein expression destabi-
lizes the CDCP1 protein, implying that KAI1 increases
VHL protein levels and reduces the levels of CDCP1.
KAI1 inhibits the induction of HIF-1a
Increased levels of Src kinase have been reported to
increase VEGF production in angiogenesis [21]. VEGF
expression, in turn, is normally up-regulated by HIF-1a
in response to decreases in oxygen concentration; in
normoxia, VHL proteins ubiquitinate and promote the
Figure 3 KAI1 increases VHL protein levels.( A) PC3 cells stably transfected with KAI1 (PC3-KAI1 #6) or vector control (PC3-GFP #8) cells were
treated with MG132. After 12 hours of treatment, cell lysates were prepared and the levels of CDCP1 were measured by immunoblotting. (B)
Cell lysates were prepared from PC3 cells transiently transfected with KAI1 and from stable transfectants. VHL expression was analyzed by
immunoprecipitation. Densitometric analysis of VHL was shown after normalization to beta-actin. (C) PC3 cells stably transfected with KAI1 (PC3-
KAI1 #5 and PC3-KAI1 #6) or vector control (PC3-GFP #8) were transiently transfected with HA-tagged VHL. Twenty-four hours after transfection,
cells were harvested, and the levels of CDCP1 and VHL protein were analyzed by immunoblotting. Densitometric analysis of HA-VHL was shown
after normalization to beta-actin. (D) PC3 cells were transfected with HA-tagged VHL, and then treated with siRNA against VHL. The protein
levels of CDCP1 and HA-VHL were assessed by immunoblotting.
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keeping HIF-1a levels and VEGF expression low [8].
Collectively, these observations form the basis for the
important idea that disruption of Src signaling leads to
suppression of cancer progression and angiogenesis. To
determine whether the inhibition of CDCP1-enhanced
Src activation by KAI1 exerts an anti-angiogenic action,
we examined the effect of KAI1 on HIF-1a, which func-
tions as a master regulator of VEGF expression. As
shown in Figure 4A, treatment with CoCl2 (100 μM),
which mimics hypoxia, increased HIF-1a levels in PC3
cells, an effect that was dramatically inhibited by transi-
ent or stable expression of KAI1. Next, GFP vector
clones (PC3-GFP#8) and KAI1 stable transfectants
(PC3-KAI1 #5 andPC3-KAI1 #6) were exposed to
hypoxia (1% O2) for 24 hours, then the effects of KAI1
on hypoxia-induced HIF-1a up-regulation were deter-
mined. Similar to the effects observed with CoCl2,H I F -
1a protein levels under hypoxic conditions were signifi-
cantly decreased by KAI1 expression (Figure 3B). There
were no changes in HIF-1a mRNA expression, suggest-
ing that these effects of KAI1 expression were posttran-
slational (Figure 3B). Interestingly, the basal levels of
HIF-1a were also diminished by KAI1 expression in
normoxic conditions (Figure 3B). As noted previously,
hypoxia did not alter HIF-1a mRNA expression [8].
Hypoxia up-regulated the CDCP1 protein, also without
changing CDCP1 mRNA levels (Figure 4B). Although
Figure 4 KAI1 blocks HIF-1a induction.( A) After transfection of KAI1, cells were treated with 100 μMC o C l 2 for 24 hours. PC3 vector control
(PC3-GFP #8) and KAI1 transfectants (PC3-KAI1 #5 and PC3-KAI1 #6) were also treated with 100 μM of CoCl2 for 24 hours. Cells were harvested
and immunoblotted for detection of HIF-1a and GFP-KAI1. Densitometric analysis of HIF-1a was shown after normalization to beta-actin. (B) PC3
vector control (PC3-GFP #8) and KAI1 transfectants (PC3-KAI1 #5 and PC3-KAI1 #6) were exposed to hypoxia for 24 hours. The levels of HIF-1a,
CDCP1, and GFP-KAI1 proteins were assessed by immunoblotting. Densitometric analysis of HIF-1a was shown after normalization to beta-actin.
HIF-1a and CDCP1 mRNA levels were measured by RT-PCR. (C) PC3 cells were cotransfected with KAI1 and HIF-1a, then treated with the
proteasome inhibitor, MG132. HIF-1a levels were assessed by immunoblotting. (D) Stable KAI1-expressing (PC3-KAI1 #6) and vector control (PC3-
GFP #8) PC3 cell clones were treated with siRNA against CDCP1 and VHL. Forty-eight hours after transfection, HIF-1a, CDCP1, and VHL protein
levels were measured by immunoblotting.
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by KAI1 (Figure 4B). Collectively, these results suggest
that KAI1 is involved in the posttranscriptional regula-
tion of HIF-1a. Because it is known that HIF-1a is
rapidly degraded under normoxia by the ubiquitin-pro-
teasome pathway, we assessed the involvement of pro-
teasomal degradation of HIF-1a in the KAI1-mediated
inhibition of HIF-1a induction. After cotransfection of
HIF-1a and KAI1, PC3 cells were treated with the pro-
teasome inhibitor MG132. KAI1 decreased the levels of
HIF-1a protein, an effect that was prevented by pre-
treatment with MG132 (Figure 4C). We also found that
depletion of VHL protein resulted in the recovery of
HIF-1a protein levels in KAI1 stable transfectants (Fig-
ure 4D), consistent with the purported role of VHL pro-
tein as a ubiquitin ligase for HIF-1a in the proteasome
degradation pathway. Thus, the CDCP1-induced
enhancement of Src activation may be deranged by the
expression of KAI1, leading to the subsequent abroga-
tion of HIF-1a induction.
KAI1 inhibits VEGF expression
Having demonstrated that KAI1 induces the degradation
of HIF-1a, we sought to determine the effect of KAI1
expression on VEGF promoter activity. For these experi-
ments, we transiently transfected PC3 cells with a luci-
ferase reporter plasmid containing a 2.2-kb region of the
VEGF promoter and measured luciferase activity. As
expected, transfection of PC3 cells with HIF-1a induced
an increase in VEGF promoter activity; notably, cotrans-
fection of KAI1 inhibited HIF-1a-induced promoter
activity (Figure 5A). Interestingly, KAI1 expression alone
decreased VEGF promoter activity (Figure 5A, C). We
also tested VEGF promoter activity in KAI1 stable trans-
fectants, cotransfecting PC3-vector clone (PC3-GFP #8)
and PC3-KAI1 stable clones (PC3-KAI1 #5 andPC3-
KAI1 #6) with an HIF-1a expression vector and the
VEGF reporter plasmid. Similar to the results shown in
Figure 5A, VEGF promoter activity was diminished in
KAI1-expressing cell lines (Figure 5B). Moreover, CoCl2
(hypoxia mimic) induced an increase in VEGF promoter
activity that was reduced by KAI1 expression (Figure
5 C ) .T h e s ed a t as u p p o r tt h eh y p o t h e s i st h a tK A I 1
induces HIF-1a degradation and subsequent transcrip-
tional inactivation of VEGF through the induction of
VHL. RT-PCR analyses, which confirmed that PC3 pros-
tate cancer cells express high levels of VEGF, showed
that KAI1 expression repressed the expression of three
VEGF isoforms (VEGF189,V E G F 165,a n dV E G F 121;F i g -
ure 5D). Since KAI1 negatively regulated CDCP1, we
treated siRNA of CDCP1 and analyzed the VEGF
expression. Knockdown of CDCP1 decreased the VEGF
level (Figure 5E). In addition, the inhibitory effect of
KAI1 on VEGF expression was also observed in the
context of CoCl2-induced up-regulation of VEGF (Fig-
ure 5F). Glucose transporter-1 (GLUT1), another tran-
scriptional target of HIF-1a, was also inhibited by KAI1
expression. Thus, the KAI1-induced decrease in HIF-1a
by KAI1 manifests as transcriptional inhibition of VEGF.
KAI1 inhibits HIF-1a and CDCP1 expression in tumor
xenografts
KAI1 is known to inhibit metastasis without affecting
primary tumorigenesis [5]. However, previous studies
have demonstrated that over-expression of KAI1 can
lead to significant cell death, described as apoptotic, or
autophagic, and caspase-independent [27-29]. In addi-
tion, we observed that KAI1 expression was associated
with dramatic down-regulation of HIF-1a and VEGF,
both of which are known to be essential for survival
under conditions of hypoxic stress. Hence, KAI1-expres-
sing cancer cells would be expected to exhibit growth
retardation or cell death. To test this, we examined the
effect of KAI1 on primary tumor formation and HIF-1a
and VEGF expression in a tumor xenograft model. The
flanks of nude mice were subcutaneously injected with
PC3-vector clone (PC3-GFP #8) or PC3-KAI1 stable
clones (PC3-KAI1 #5 andPC3-KAI1 #6). Five weeks
after injection, mice were sacrificed and tumor volumes
were measured. As shown in Figure 6A, the volume of
tumors was significantly reduced in mice injected with
KAI1 stable transfectants( P C 3 - K A I 1# 5a n dP C 3 -
KAI1#6) compared with those injected with PC3 vector
cell lines (PC3-GFP #8). These data suggest that KAI1
expression disrupted the ability of cancer cells in solid
tumors to acquire the metastatic potential necessary to
overcome hypoxic stress. Next, we performed immuno-
histochemistry to detect HIF-1a, CDCP1 and VHL pro-
tein in tumor tissue. The analyses showed that CDCP1
proteins were barely detectable in tumors derived from
KAI1-expressing cell lines; in contrast, VHL immunor-
eactivity coincided with KAI1 expression. With our
expectation, HIF-1a level in KAI1 expressing tumor was
significantly low as compared with control (Figure 6B).
These results correlate well with our protein expression
data obtained from immunoblot analyses. Collectively,
these observations demonstrate that the metastasis-sup-
pressive activity of KAI1 is highly relevant to the down-
regulation of CDCP1 and suppression of HIF-1a expres-
sion in prostate cancer.
Discussion
The purpose of this study was to establish the precise
mechanism by which KAI1 (CD82), a metastasis-sup-
pressor gene initially discovered in prostate cancer, inhi-
bits Src and affects the metastasis of prostate carcinoma.
Clinical cancer studies have linked a high level of KAI1
expression with a good prognosis. Conversely, the loss
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tumor progression [3,5]. However, how KAI1 functions
to suppress metastasis has not yet been clearly estab-
lished. Tetraspanins, including KAI1, may play a role in
the plasma membrane as organizers of multi-molecular
complexes that contain not only tetraspanins but also
numerous cell membrane components. The TEM has
been suggested to serve as a signal-networking platform
that shifts the characteristics of a cancer between pri-
mary tumor and a metastatic phenotype [30,31]. Thus, it
is of special interest to define the constituents of this
special domain and their interrelationships.
Current studies have proposed that KAI1 functions to
inhibit Src kinase activity, but the identified mechanisms
have been limited to associations with integrins, EGFR,
and c-Met [5]. It has been proposed that KAI1 attenu-
ates EGFR signaling and inhibits cell motility in breast
cancer [32]. However, other study reported no alteration
of EGFR signaling in response to KAI1 expression in
DU145 and PC3 prostate cancer cell lines [18]. It is gen-
erally accepted that c-Met can play a role in the metas-
tasis-suppression activity of KAI1 in prostate cancer
[33,34]; however, inhibition of this pathway and Src
kinase by KAI1 expression appear to be independent of
Figure 5 KAI1 decreases VEGF expression.( A) PC3 cells were cotransfected with a VEGF promoter (2.2 kb)-luciferase reporter plasmid and HIF-
1a and GFP-KAI1 expression plasmids. Forty-eight hours after transfection, cell lysates were analyzed for luciferase expression. (B) PC3 cells stably
transfected with KAI1 (PC3-KAI1 #5 and PC3-KAI1 #6) or vector control (PC3-GFP #8) were cotransfected with a VEGF promoter-luciferase reporter
plasmid and a HIF-1a expression vector. Forty-eight hours after transfection, cell lysates were analyzed for luciferase activity. (C) PC3 cells were
cotransfected with a VEGF promoter-luciferase reporter plasmid and a GFP-KAI1 expression plasmid. Twenty-four hours after transfection, cells
were treated with 100 μM CoCl2 for 24 hours, and then luciferase activity was measured. (D) Total RNA from PC3 cells stably transfected with
KAI1 (PC3-KAI1 #5 and PC3-KAI1 #6) or vector control (PC3-GFP #8) was isolated, and VEGF mRNA expression was analyzed by RT-PCR. (E) After
treatment of si-CDCP1, PC3 cells were harvested and VEGF mRNA expression was analyzed by RT-PCR. (F). PC3 cells stably transfected with KAI1
(#6) or vector control (PC3-GFP #8) were exposed to CoCl2 (100 μM) for 24 hours. Total RNA was extracted and mRNA levels were quantified by
RT-PCR.
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vious report [35], we found no connection between
integrin complexes and Src inhibition, showing that
depletion of integrin b1, the major component of integ-
rin complexes, had no specific effect on Src phosphory-
lation status but decrease of phosphorylated FAK and
p130CAS, downstream effector of integrin complexes, in
PC3 cells (Figure 2A). Therefore, the absence of a con-
nection between these KAI1 targets and inhibition of
Src kinase activity prompted us to investigate another
target of KAI1.
Together with KAI1, CDCP1 has been reported to be
a component of the TEM in colon cancer, but its func-
tion in this context has remained poorly characterized
[11]. CDCP1 is a transmembrane protein that primarily
associates with Src and PKCδ in a phosphorylation-
dependent manner and may act as a scaffold for various
interacting proteins in the plasma membrane [12]. Gen-
erally, CDCP1 is highly phosphorylated and functionally
activated in metastatic cancer; dysregulated expression
of CDCP1 is associated with tumor malignancy
[14,36-38]. Tyrosine phosphorylated CDCP1 has been
linked to cell detachment from the extracellular matrix
and subsequent cell migration [39]. The kinase activity
of Src is essential for the initial CDCP1 phosphorylation;
Src-activated CDCP1, in turn, further potentiates Src
kinase activity [25,40], although the mechanism for this
latter effect is not clear. Our data showed that KAI1-
induced inhibition of CDCP1 protein resulted in an
almost complete elimination of Src phosphorylation
(Figure 2F). This observation suggests that the function
of CDCP1 protein, which acts as a positive regulator of
Src kinase, may be lost due to KAI1 expression in pros-
tate cancer, raising the question of the possible existence
of a feedback control mechanism between CDCP1 and
Src.
CDCP1 gene regulation has been investigated in var-
ious cancer cell lines. PC3 cells show abundant expres-
sion of CDCP1 protein and a low frequency of
methylation in transcription-initiation sites [41]. We
f o u n dt h a tb o t hH M Wa n dL M Wf o r m so fC D C P 1a r e
expressed in PC3 cells (Figure 2). Although the precise
mechanism by which CDCP1 is cleaved has not been
defined, proteolytic processing by a serine protease
Figure 6 KAI1 inhibits HIF-1a and CDCP1 expression and VEGF secretion in tumor xenografts.( A) PC3 cells stably transfected with KAI1
(PC3-KAI1 #5 andPC3-KAI1 #6) or vector control (PC3-GFP #8) were resuspended in PBS (2 × 10
6 cells/100 μl) and injected subcutaneously into
the flanks of athymic nude mice. Animals were sacrificed 35 days after injection, at which time tumors were collected and photographed. Tumor
volumes were measured using precision calipers (B) Photomicrographs showing expression of HIF-1a, CDCP1, and VHL protein in tumor sections
by immunohistochemistry.
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and a subsequent increase in LMW phosphorylation
[24]. Our data clearly showed that KAI1 expression
decreased the level of both HMW and LMW forms
without altering CDCP1 mRNA levels (Figure 2), sug-
gesting that the KAI 1-induced decrease in CDCP1 in
PC3 cells reflects the operation of a posttranscriptional
mechanism. To test this, we initially treated PC3 cells
with cytochalasin D, which blocks cytoskeletal move-
ment, with the goal of determining whether KAI1
affected the endocytic trafficking of CDCP1. We found
no effect of this actin-depolymerizing reagent on the
KAI1-induced decrease in CDCP1 (data not shown). As
demonstrated in previously reported proteomic analyses,
CDCP1 and KAI1 are colocalized with various proteases
i nt h eT E M[ 1 1 ] ,r a i s i n gt h ep o s s i b l ei n v o l v e m e n to f
KAI1 in protease activity. Since serine protease-induced
proteolysis of CDCP1 has been documented [24], we
treated PC3 cells with protease inhibitors and monitored
the levels of CDCP1 under conditions of KAI1 over-
expression, but found no significant change in either
HMW or LMW forms of CDCP1 (data not shown).
Finally, to test the involvement of proteasome-depen-
dent degradation in the process of CDCP1 down-regula-
tion, we treated PC3 cells with the proteasome inhibitor,
MG132, and found that inhibiting the proteasome pre-
vented the KAI1-dependent reduction in CDCP1 levels
(Figure 3A). Because CDCP1 is reported to localize in
the TEM of colon cancer by proteomic analysis, we
could not exclude a possible interaction between KAI1
and CDCP1. In experiments designed to determine
whether these two membrane proteins were co-localized
in PC3 cells, it was hard to detect an interaction of
CDCP1 with KAI1 due to KAI1-induced loss of CDCP1
protein level. Our observations indicate that KAI1-
induced down-regulation of CDCP1 reflects effects on
CDCP1 protein stability, but unknown mechanisms may
also participate in this phenomenon.
Angiogenesis is an indispensible step in the progres-
sion of prostate cancer, and VEGF has emerged as a cri-
tical proangiogenic growth factor in prostate
carcinogenesis [22,42,43]. Hypoxia is the environmental
factor best known for its ability to induce cancer metas-
tasis; it also stabilizes HIF-1a and up-regulates the
expression of VEGF, which, in turn, induces the forma-
tion of tumor-feeding vessels [6]. Moreover, it is known
that Src kinase not only affects cell proliferation and
migration, it also control angiogenesis via up-regulation
of VEGF expression [44]. However, few studies have
focused on the role of KAI1 activity in VEGF expression
and vasculature formation in tumors. Thus, given the
critical role of KAI1 in inhibiting Src kinase and our
motivation to identify a plausible mechanism to account
for KAI1 effects in carcinogenesis, we examined HIF-1a
a n dV E G Fe x p r e s s i o ni nt h ec o n t e x to fK A I 1e x p r e s -
sion. We found that HIF-1a and VEGF expression were
dramatically inhibited upon restoration of KAI1 expres-
sion (Figures 4 and 5). These findings were supported
by the results obtained using an in vivo xenograft
model, which showed that KAI1-expressing tumor
volumes were significantly reduced compared with
those of controls (Figure 6). Moreover, whereas CDCP1
and HIF-1a expression were reduced in KAI1-expres-
sing tumor tissue, VHL expression was clearly augmen-
ted. Thus, our data provide a mechanistic basis for the
clear correlation between the loss of KAI1 in cancer
and poor prognosis. It has recently been demonstrated
that Src can promote oncogenesis through destabiliza-
tion of the VHL tumor suppressor [26]. Importantly,
functional inactivation of VHL, including through germ-
line mutations, has been well documented in highly vas-
cularized tumors such as renal cell carcinomas,
hemangiosarcomas, and pheochromocytomas [9]. The
tumor-suppressive function of VHL is best viewed in
the context of its role as an E3 ubiquitin ligase that tar-
gets various substrates, including HIF-1a and atypical
PKC [8]. Two forms of VHL, approximately 30 and 18
kDa, exist, but the significance of the two forms is
unknown [45]. It has been suggested that VHL is extre-
mely unstable when not complexed with components of
ubiquitin ligase complexes, such as elongin B and elon-
gin C [9]. This observation may account for the diffi-
culty in detecting VHL protein expression and may help
to explain why most VHL functions have been exam-
ined by overexpressing or immunoprecipitating VHL.
We observed that VHL protein levels were increased by
KAI1 expression (Figure 3B, C). How KAI1 negatively
regulates CDCP1 remains uncertain, but our data
clearly suggest that this effect of KAI1 involves the reg-
ulation of CDCP1 protein stability. Intriguingly, VHL
over-expression decreased CDCP1 levels; this result was
confirmed by treating cells with siRNA against VHL,
which had the opposite effect on CDCP1 levels (Figure
3D). VHL protein is expressed in various normal and
cancer tissues, where it is localized in the cytosol or
membrane [46]. In human renal cell carcinoma, its pre-
sence in the membrane is significantly associated with a
missense mutation [10,47]. These reports prompted us
to further consider changes in subcellular localization of
VHL in the process of tumorigenesis. In addition, we
observed the existence of VHL in both of cytosol and
membrane fractions in VHL overexpressing PC3 cells
(data not shown). This observation raises the possibility
of recruitment of VHL from cytosol to plasma mem-
brane and ubiquitination of unknown substrates located
in the membrane. Although we could not observe co-
localization of CDCP1, VHL and KAI1 in cell mem-
brane or TEM, these proteins would be expected to
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prostate carcinogenesis.
Conclusion
We report here that KAI1 acts in the process of tumor
malignancy and angiogenesis by profoundly suppressing
metastasis via inhibition of CDCP1-enhanced Src activa-
tion and functional activation of VHL. This KAI1-
induced VHL activation causes HIF-1a degradation and,
ultimately, down-regulation of VEGF expression. These
results provide insight into how KAI1 suppresses pros-
tate cancer metastasis. Although we focused our efforts
here on CDCP1-Src inhibition by KAI1 and their effects
on VEGF expression, KAI1 expression may also influ-
ence other key processes in prostate carcinogenesis.
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